Correction: Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer

Lili Yang; Shanshan Liu; Jingjing Chu; Shuang Miao; Kai Wang; Qingwei Zhang; Yingyi Wang; Yadi Xiao; Lina Wu; Yang Liu; Longjian Yu; Caihong Yu; Xiang Liu; Mingxing Ke; Zhen Cheng; Xilin Sun

doi:10.1039/D2BM90028A

Correction: Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer

Lili Yang,^ab Shanshan Liu,^ab Jingjing Chu,^a Shuang Miao,^ab Kai Wang,^ab Qingwei Zhang,^ab Yingyi Wang,^a Yadi Xiao,^a Lina Wu,^ab Yang Liu,^ab Longjian Yu,^ab Caihong Yu,^ab Xiang Liu,^ab Mingxing Ke,^ab Zhen Cheng*^c and Xilin Sun*^ab

Author affiliations

* Corresponding authors

^a NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, Harbin, Heilongjiang, China

^b TOF-PET/CT/MR Center, The Fourth Hospital of Harbin Medical University, Harbin, Heilongjiang, China
E-mail: sunxl@ems.hrbmu.edu.cn
Tel: +86-451-88118600

^c Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University School of Medicine, Stanford, California 94305, USA
E-mail: zcheng@stanford.edu
Fax: +1-650-736-7925

Abstract

Correction for ‘Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer’ by Lili Yang et al., Biomater. Sci., 2021, 9, 443–455. DOI: 10.1039/D0BM00293C.

Biomaterials Science

Correction: Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer

Abstract

Associated articles

Article information

Download Citation

Permissions

Correction: Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer

Social activity

Search articles by author

Spotlight

Advertisements